Active Ingredient History

  • Now
Conatumumab is a monoclonal antibody developed for the treatment of cancer. It is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL receptor 2 with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.   Wikipedia

More Chemistry
amg655 | amg 655 | amg-655 | azd1940 | conatumumab | n-(2-tert-butyl-1-((4,4-difluorocyclohexyl)methyl)-1h-benzo(d)imidazol-5-yl)ethanesulfonamide | trail-r2 mab | xg1-048


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue